Lupin inks pact to acquire two inhalation brands from Sunovion for $ 75 mn

Lupin will acquire two inhalation brands from Sunovion Pharmaceuticals Inc for $ 75 mn (around INR 622 crore). The drug firm has inked a pact with US-based Sunovion to acquire Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol.